Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Autor: | Pipe, Steven W, Shima, Midori, Lehle, Michaela, Shapiro, Amy, Chebon, Sammy, Fukutake, Katsuyuki, Key, Nigel S, Portron, Agnès, Schmitt, Christophe, Podolak-Dawidziak, Maria, Selak Bienz, Nives, Hermans, Cedric, Campinha-Bacote, Avrita, Kiialainen, Anna, Peerlinck, Kathelijne, Levy, Gallia G, Jiménez-Yuste, Victor |
---|---|
Zdroj: | In The Lancet Haematology June 2019 6(6):e295-e305 |
Databáze: | ScienceDirect |
Externí odkaz: |